“医药一哥”重磅消息！恒瑞医药公布两款药品新进展

Group 1 - Company received conditional approval from the National Medical Products Administration for its innovative drug, SHR2554, which is the first EZH2 inhibitor developed in China, aimed at treating adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) [1][5] - The development cost for SHR2554 has reached approximately 213 million yuan [5] - Peripheral T-cell lymphoma (PTCL) accounts for about 25% to 30% of non-Hodgkin lymphoma cases in China, with a median onset age of 52 years, indicating a younger patient demographic [5] Group 2 - The company’s subsidiary, Fujian Shengdi Pharmaceutical, received a notice of acceptance for the drug application of HRS9531 injection, which is intended for long-term weight management in adults [3][5] - HRS9531 aims to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [5] - Cumulative R&D investment for HRS9531 has reached approximately 45.235 million yuan [6] Group 3 - In the first half of 2025, the company achieved a revenue of 15.761 billion yuan, representing a year-on-year growth of 15.88%, with a net profit of 4.450 billion yuan, up 29.67% [7] - Innovative drug sales and licensing revenue accounted for 60.66% of total revenue, with innovative drug sales reaching 7.570 billion yuan [8] - The company is focused on developing first-in-class and best-in-class molecules, supported by 14 global R&D centers [7][8]